Share on LinkedInShare on LinkedIn

ARTICLE · 30 OCTOBER 2015

AstraZeneca And Ranbaxy Avoid Heartburn Of A New Antitrust Trial

In order to succeed, the plaintiffs had to prove the no-AG clauses caused "an 'antitrust injury'—a real-world impact on the relevant market from the alleged monopolistic practice or practices."

United StatesIntellectual Property

In re Nexium (Esomeprazole) Antitrust Litigation, (D. Mass., August 7, 2015)

On August 7, 2015, Judge William G. Young, of the U.S. District Court for the District of Massachusetts, denied Plaintiffs' post-trial motions seeking a new trial and entry of a permanent injunction in this complex, multi-district pharmaceutical antitrust litigation. These motions followed an October 2014 jury trial based on alleged antitrust violations stemming from reverse payment settlements between AstraZeneca (the manufacturer of heartburn medication, Nexium®) and generic manufacturers (Ranbaxy, Teva and Dr. Reddy's Laboratories). Specifically, each settlement agreement AstraZeneca entered with generic manufacturers to end the Hatch-Waxman patent suit included a "no authorized generic clause." The antitrust case was instituted by classes of plaintiffs (including wholesale drug distributors, end-payers and pharmaceutical retail outlets) claiming that the settlements between AstraZeneca

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from